3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
11
ruxolitinib
10
fludarabine phosphate
9
Tacrolimus
7
Filgrastim
7
fludarabine
6
Decitabine
6
Whole-Body Irradiation
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Busulfan
5
navitoclax
4
Sirolimus
4
Etoposide
4
Azacitidine
4
Specimen Handling
3
Methylprednisolone
3
Methotrexate
3
Melphalan
3
Cyclosporine
3
Antilymphocyte Serum
3
venetoclax
2
thymoglobulin
2
durvalumab
2
Vorinostat
2
Thiotepa
2
Sunitinib
2
Stem Cell Transplantation
2
Radiotherapy
2
Prednisone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Primary Myelofibrosis
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled